# Agendia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/agendia

- Industry: Biotechnology
- Headquarters: Irvine, US
- Website: www.agendia.com
- Total disclosed funding: $65M
- Latest round: Series E (Sep 23, 2009)
- Investors on record: 6

## About

Agendia, Inc. is a biotechnology company focused on precision medicine for breast cancer management through its advanced genomic testing solutions, designed to enhance patient-specific treatment plans.Founded in 2003 and headquartered in Irvine, US, Agendia, Inc. specializes in genomic testing for breast cancer. The company has successfully raised USD 35.00 mn in venture funding, with the latest round occurring on July 25, 2018, led by Athyrium Capital Management. The founder, Rene Bernards, has a background in developing diagnostic solutions prior to Agendia. The firm has engaged in a total of 11 deals to date.Agendia offers genomic testing solutions, primarily through its products MammaPrint and BluePrint. These tests are designed to evaluate the genomic characteristics of tumors to predict breast cancer recurrence and identify molecular subtypes. The insights provided by these tests facilitate the creation of tailored treatment strategies that help avoid both under-treatment and over-treatment in patients. Their services are employed by healthcare providers, including oncologists and hospitals, across diverse markets, notably in the US, Canada, parts of South America, and Europe, with a significant presence in the Netherlands.In the most recent financial year, Agendia reported revenue of USD 57.89 mn, with an EBITDA loss of USD 18.02 mn.Following the successful funding round in July 2018, Agendia plans to utilize the raised USD 35.00 mn for expanding its commercial presence in both the U.S. and international markets. The company aims to establish new collaborative research programs to enhance its product offerings and increase market penetration. Agendia is focused on releasing new products to strengthen its portfolio and meet the rising demand for precision genomic insights in breast cancer management.

## Funding rounds

- Series E, Sep 23, 2009, $23M — Global Life Science Ventures, Gilde Healthcare, Van Herk Group, ING Ventures
- Series D, Aug 28, 2007, $36M — Global Life Science Ventures, Gilde Healthcare, Van Herk Group, ING Ventures
- Series C, Jun 2, 2006 — Gilde Healthcare, Van Herk Group
- Series B, Oct 11, 2005 — Van Herk Group
- Series A, Mar 30, 2004, $6.1M — Ardian, Global Life Science Ventures, Gilde Healthcare, AXA Venture Partners

## Investors

- Ardian (https://capitalatlas.ai/funds/ardian) — Series A
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series A, Series D, Series E
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series C, Series D, Series E
- AXA Venture Partners (https://capitalatlas.ai/funds/axa-venture-partners) — Series A
- Van Herk Group (https://capitalatlas.ai/funds/van-herk-group) — Series B, Series C, Series D, Series E
- ING Ventures (https://capitalatlas.ai/funds/ing-ventures) — Series D, Series E